PT010 Inhaler for Asthma (KALOS Trial)

"In order to be included in this clinical trial, patients must be aged 12-80. There are many other options available for younger or older patients, with 130 trials and 239 trials respectively."

"This trial is looking for 2200 patients that suffer from asthma and meet the following additional requirements: Being between 12-80 years old, of any gender, with a BMI below 40 kg/m2. If female, they must be unable to bear children or using birth control. For participants aged 12-18, their post-albuterol FEV1 at V2 or V3 (if needed) must be under 90%. There needs to be a documented history of physician diagnosed asthma from 1 year prior to study start date. All participants much have been regularly taking ICS/LABA medication with stable doses for 4 weeks before"

"That is correct. The trial, which was initially posted on December 15th 2020 and last updated September 15th 2022, is still recruiting patients according to information available on clinicaltrials.gov. There are 97 different medical centres looking for a total of 2200 individuals to participate in the study."

"BGF MDI 320/14.4/9.6 μg can be used to effectively treat patients that experience reflex, trigeminocardiac, bodily secretions, and rapid anticholinergic effect side-effects."

"At the moment, this clinical trial is being conducted at 97 sites. Some of these locations are in Toms River, Burlington and Boerne. There are also 97 other locations. If you want to participate in this trial, it would be ideal to select a site nearest to your location to reduce travel time commitment."

"First researched in 2007 at Arthur F. Gelb Medical Corporation, BGF MDI 320/14.4/9.6 μg has completed 541 clinical trials as of now. Currently, 47 studies are ongoing with a large number of them taking place in Toms River, New jersey."

"The primary outcome of this over a 24-week period is the rate of severe asthma exacerbations. Additionally, the study will measure the percentage of responders in ACQ-5 (≥0.5 decrease equals response) at Week 24, time to first moderate/severe asthma exacerbation, and the percentage of responders in the St. George's Respiratory Questionnaire (SGRQ) (≥4.0 unit decrease equals response) at Week 24."

"Yes, you are correct. The clinicaltrials.gov website has information indicating that this study is looking for participants. The trial was first posted on December 15th 2020 and was last updated September 15th 2022. They are recruiting 2200 individuals from 97 different sites."

"BGF MDI 320/14.4/9.6 μg's safety is estimated to be a 3. This estimate comes from the fact that this is a Phase 3 trial, meaning there is evidence of efficacy as well as multiple rounds of data supporting safety."